Pallab Sanpui
Research Subjects
Pallab Sanpui has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Siddhartha Sankar Ghosh
Indian Institute of Technology Guwahati
14 shared publications - Arun Chattopadhyay
Indian Institute of Technology Guwahati
10 shared publications - Anumita Paul
Department of Chemistry, Indian Institute of Technology Guwahati, Guwahati 781039, India
5 shared publications Arun Chattopadhyay
Department of Chemistry and ‡ Centre for Nanotechnology, Indian Institute of Technology Guwahati , Guwahati 781039, Assam, India
5 shared publicationsSiddhartha Sankar Ghosh
Department of Biotechnology
5 shared publicationsAnil Parsram Bidkar
Department of Biosciences & Bioengineering, Indian Institute of Technology Guwahati, Guwahati 39, Assam, India
3 shared publications
Latest Publications
- 15 August 2026
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 268
Optimization and evaluation of curcumin-loaded zein microneedles for potential treatment of melanoma
- 15 August 2026
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 268
Optimization and evaluation of curcumin-loaded zein microneedles for potential treatment of melanoma
- 9 May 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 314, 143898
Tyrosine kinase inhibitor-loaded zein nanoparticles with enhanced drug delivery and anticancer efficacy
- 9 May 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 314, 143898
Tyrosine kinase inhibitor-loaded zein nanoparticles with enhanced drug delivery and anticancer efficacy
- 16 October 2024
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 245, 114319
Curcumin-loaded zein nanoparticles: A quality by design approach for enhanced drug delivery and cytotoxicity against cancer cells
- 16 October 2024
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 245, 114319
Curcumin-loaded zein nanoparticles: A quality by design approach for enhanced drug delivery and cytotoxicity against cancer cells
- 21 September 2023
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 9 (10) , 5527-5547
Human Hair Keratin-Based Hydrogels in Regenerative Medicine: Current Status and Future Directions
Regenerative medicine (RM) is a multidisciplinary field that utilizes the inherent regenerative potential of human cells to generate functionally and physiologically acceptable human cells, tissues, and organs in vivo or ex vivo. An appropriate biomaterial scaffold with desired physicochemical properties constitutes an important component of a successful RM approach. Among various forms of biomaterials explored until the present day, hydrogels have emerged as a versatile candidate for tissue engineering and regenerative medicine (TERM) applications such as scaffolds for spatial patterning and delivering therapeutic agents, or substrates to enhance cell growth, differentiation, and migration. Although hydrogels can be prepared from a variety of synthetic polymers as well as biopolymers, the latter are preferred for their inherent biocompatibility. Specifically, keratins are fibrous proteins that have been recently explored for constructing hydrogels useful for RM purposes. The present review discusses the suitability of keratin-based biomaterials in RM, with a particular focus on human hair keratin hydrogels and their use in various RM applications.
- 21 September 2023
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 9 (10) , 5527-5547
Human Hair Keratin-Based Hydrogels in Regenerative Medicine: Current Status and Future Directions
Regenerative medicine (RM) is a multidisciplinary field that utilizes the inherent regenerative potential of human cells to generate functionally and physiologically acceptable human cells, tissues, and organs in vivo or ex vivo. An appropriate biomaterial scaffold with desired physicochemical properties constitutes an important component of a successful RM approach. Among various forms of biomaterials explored until the present day, hydrogels have emerged as a versatile candidate for tissue engineering and regenerative medicine (TERM) applications such as scaffolds for spatial patterning and delivering therapeutic agents, or substrates to enhance cell growth, differentiation, and migration. Although hydrogels can be prepared from a variety of synthetic polymers as well as biopolymers, the latter are preferred for their inherent biocompatibility. Specifically, keratins are fibrous proteins that have been recently explored for constructing hydrogels useful for RM purposes. The present review discusses the suitability of keratin-based biomaterials in RM, with a particular focus on human hair keratin hydrogels and their use in various RM applications.
- 11 August 2023
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 15 (33) , 39081-39098
Palladium Nanocapsules for Photothermal Therapy in the Near-Infrared II Biological Window
Recent developments in nanomaterials with programmable optical responses and their capacity to modulate the photothermal effect induced by an extrinsic source of light have elevated plasmonic photothermal therapy (PPTT) to the status of a favored treatment for a variety of malignancies. However, the low penetration depth of near-infrared-I (NIR-I) lights and the need to expose the human body to a high laser power density in PPTT have restricted its clinical translation for cancer therapy. Most nanostructures reported to date exhibit limited performance due to (i) activity only in the NIR-I region, (ii) the use of intense laser, (iii) need of large concentration of nanomaterials, or (iv) prolonged exposure times to achieve the optimal hyperthermia state for cancer phototherapy. To overcome these shortcomings in plasmonic nanomaterials, we report a bimetallic palladium nanocapsule (Pd Ncap)─with a solid gold bead as its core and a thin, perforated palladium shell─with extinction both in the NIR-I as well as the NIR-II region for PPTT applications toward cancer therapy. The Pd Ncap demonstrated exceptional photothermal stability with a photothermal conversion efficiency of ∼49% at the NIR-II (1064 nm) wavelength region at a very low laser power density of 0.5 W/cm2. The nanocapsules were further surface-functionalized with Herceptin (Pd Ncap-Her) to target the breast cancer cell line SK-BR-3 and exploited for in vitro PPTT applications using NIR-II light. Pd Ncap-Her caused more than 98% cell death at a concentration of just 50 μg/mL and a laser power density of 0.5 W/cm2 with an output power of only 100 mW. Flow cytometric and microscopic analyses revealed that Pd Ncap-Her-induced apoptosis in the treated cancer cells during PPTT. Additionally, Pd Ncaps were found to have reactive oxygen species (ROS) scavenging ability, which can potentially reduce the damage to cells or tissues from ROS produced during PPTT. Also, Pd Ncap demonstrated excellent in vivo biocompatibility and was highly efficient in photothermally ablating tumors in mice. With a high photothermal conversion and killing efficiency at very low nanoparticle concentrations and laser power densities, the current nanostructure can operate as an effective phototherapeutic agent for the treatment of different cancers with ROS-protecting ability.
- 11 August 2023
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 15 (33) , 39081-39098
Palladium Nanocapsules for Photothermal Therapy in the Near-Infrared II Biological Window
Recent developments in nanomaterials with programmable optical responses and their capacity to modulate the photothermal effect induced by an extrinsic source of light have elevated plasmonic photothermal therapy (PPTT) to the status of a favored treatment for a variety of malignancies. However, the low penetration depth of near-infrared-I (NIR-I) lights and the need to expose the human body to a high laser power density in PPTT have restricted its clinical translation for cancer therapy. Most nanostructures reported to date exhibit limited performance due to (i) activity only in the NIR-I region, (ii) the use of intense laser, (iii) need of large concentration of nanomaterials, or (iv) prolonged exposure times to achieve the optimal hyperthermia state for cancer phototherapy. To overcome these shortcomings in plasmonic nanomaterials, we report a bimetallic palladium nanocapsule (Pd Ncap)─with a solid gold bead as its core and a thin, perforated palladium shell─with extinction both in the NIR-I as well as the NIR-II region for PPTT applications toward cancer therapy. The Pd Ncap demonstrated exceptional photothermal stability with a photothermal conversion efficiency of ∼49% at the NIR-II (1064 nm) wavelength region at a very low laser power density of 0.5 W/cm2. The nanocapsules were further surface-functionalized with Herceptin (Pd Ncap-Her) to target the breast cancer cell line SK-BR-3 and exploited for in vitro PPTT applications using NIR-II light. Pd Ncap-Her caused more than 98% cell death at a concentration of just 50 μg/mL and a laser power density of 0.5 W/cm2 with an output power of only 100 mW. Flow cytometric and microscopic analyses revealed that Pd Ncap-Her-induced apoptosis in the treated cancer cells during PPTT. Additionally, Pd Ncaps were found to have reactive oxygen species (ROS) scavenging ability, which can potentially reduce the damage to cells or tissues from ROS produced during PPTT. Also, Pd Ncap demonstrated excellent in vivo biocompatibility and was highly efficient in photothermally ablating tumors in mice. With a high photothermal conversion and killing efficiency at very low nanoparticle concentrations and laser power densities, the current nanostructure can operate as an effective phototherapeutic agent for the treatment of different cancers with ROS-protecting ability.
- 6 October 2022
- Published by Springer Nature in Journal of Material Cycles and Waste Management
- Vol. 25 (1) , 1-16
Extraction of keratin from keratinous wastes: current status and future directions
- 6 October 2022
- Published by Springer Nature in Journal of Material Cycles and Waste Management
- Vol. 25 (1) , 1-16
Extraction of keratin from keratinous wastes: current status and future directions
- 10 March 2020
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 3 (4) , 3807-3819
Transferrin-Conjugated Red Blood Cell Membrane-Coated Poly(lactic-co-glycolic acid) Nanoparticles for the Delivery of Doxorubicin and Methylene Blue
- 10 March 2020
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 3 (4) , 3807-3819
Transferrin-Conjugated Red Blood Cell Membrane-Coated Poly(lactic-co-glycolic acid) Nanoparticles for the Delivery of Doxorubicin and Methylene Blue
- 17 August 2019
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 2 (9) , 4077-4086
Red Blood Cell-Membrane-Coated Poly(Lactic-co-glycolic Acid) Nanoparticles for Enhanced Chemo- and Hypoxia-Activated Therapy
Herein, a membrane-coated nanocarrier for codelivery of chemotherapeutic agents, curcumin (Cur) and the hypoxia-activated molecule, tirapazamine (TPZ), has been developed. Cur and TPZ were loaded into biodegradable poly(lactic-co-glycolic acid) nanoparticles (PLGA NPs) and finally coated with red blood cell (RBC) membrane by an extrusion process. Characterization of drug-loaded membrane-coated NPs ([email protected]) by dynamic light scattering, TEM and FESEM analyses showed that the NPs were of 105 nm size with a surface charge of −31 mV. Experimental results demonstrated long-term stability, biocompatibility and efficient cellular internalization (primarily through caveolin mediated pathway) of the [email protected] Antiproliferative studies on 2D monolayer as well as hypoxic 3D multicellular spheroids (MCS) confirmed that the drug-loaded NPs were more potent than free drugs, inducing apoptosis via generation of reactive oxygen species and consequent DNA damage. Furthermore, the reduced cell migration in the scratch assay and down regulations mesenchymal markers as a result of [email protected] treatment suggest the potential of the present system in circumventing hypoxic solid tumors.
- 17 August 2019
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 2 (9) , 4077-4086
Red Blood Cell-Membrane-Coated Poly(Lactic-co-glycolic Acid) Nanoparticles for Enhanced Chemo- and Hypoxia-Activated Therapy
Herein, a membrane-coated nanocarrier for codelivery of chemotherapeutic agents, curcumin (Cur) and the hypoxia-activated molecule, tirapazamine (TPZ), has been developed. Cur and TPZ were loaded into biodegradable poly(lactic-co-glycolic acid) nanoparticles (PLGA NPs) and finally coated with red blood cell (RBC) membrane by an extrusion process. Characterization of drug-loaded membrane-coated NPs ([email protected]) by dynamic light scattering, TEM and FESEM analyses showed that the NPs were of 105 nm size with a surface charge of −31 mV. Experimental results demonstrated long-term stability, biocompatibility and efficient cellular internalization (primarily through caveolin mediated pathway) of the [email protected] Antiproliferative studies on 2D monolayer as well as hypoxic 3D multicellular spheroids (MCS) confirmed that the drug-loaded NPs were more potent than free drugs, inducing apoptosis via generation of reactive oxygen species and consequent DNA damage. Furthermore, the reduced cell migration in the scratch assay and down regulations mesenchymal markers as a result of [email protected] treatment suggest the potential of the present system in circumventing hypoxic solid tumors.
- 27 June 2019
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 2 (8) , 3144-3152
Protein–Nanoparticle Agglomerates as a Plasmonic Magneto-Luminescent Multifunctional Nanocarrier for Imaging and Combination Therapy
We report the fabrication of a plasmonic-magneto-luminescent multifunctional nanocarrier (PML-MF nanocarrier) by lysozyme-mediated agglomeration of gold-coated iron-oxide nanoparticles ([email protected]) and subsequent coating of these agglomerates with BSA-stabilized gold nanoclusters (BSA-AuNCs). Agglomeration-mediated enhancement of plasmonic absorbance at NIR-biological window helped in plasmonic photothermal therapy (PPTT) by PML-MF nanocarriers. PML-MF nanocarriers demonstrated excellent in vitro bioimaging and magnetic targeting capabilities due to strong photoluminance and superparamagnetism of the constituent AuNCs and [email protected], respectively. Moreover, these nanocarriers showed successful loading and delivery of doxorubicin to cancer cells with significant killing efficiency that could be synergistically improved by combining with PPTT.
- 27 June 2019
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 2 (8) , 3144-3152
Protein–Nanoparticle Agglomerates as a Plasmonic Magneto-Luminescent Multifunctional Nanocarrier for Imaging and Combination Therapy
We report the fabrication of a plasmonic-magneto-luminescent multifunctional nanocarrier (PML-MF nanocarrier) by lysozyme-mediated agglomeration of gold-coated iron-oxide nanoparticles ([email protected]) and subsequent coating of these agglomerates with BSA-stabilized gold nanoclusters (BSA-AuNCs). Agglomeration-mediated enhancement of plasmonic absorbance at NIR-biological window helped in plasmonic photothermal therapy (PPTT) by PML-MF nanocarriers. PML-MF nanocarriers demonstrated excellent in vitro bioimaging and magnetic targeting capabilities due to strong photoluminance and superparamagnetism of the constituent AuNCs and [email protected], respectively. Moreover, these nanocarriers showed successful loading and delivery of doxorubicin to cancer cells with significant killing efficiency that could be synergistically improved by combining with PPTT.
- 22 March 2019
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 5 (5) , 2222-2234
Combination Therapy with MAPK-Pathway-Specific Inhibitor and Folic-Acid-Receptor-Targeted Selenium Nanoparticles Induces Synergistic Antiproliferative Response in BRAF Mutant Cancer Cells
Combination chemotherapy, where drugs with non-overlapping mode of actions achieve better efficacy at lower doses with reduced dose-dependent side effects, holds promise for complete remission of tumor. Herein, we report a combination therapeutic module comprised of folic acid receptor (FAR)-targeted SeNPs (FA-SeNPs) and MAPK pathway inhibitor PD98059 (PD98). While aberrant signaling leading to uncontrolled proliferation in BRAF-mutation bearing cancer cells including MDAMB231 (breast cancer) and A375 (melanoma) cells was inhibited by PD98, high expression of FAR by these cells also led to selective internalization of FA-SeNPs. Consequently, the combination treatment of PD98 and FA-SeNPs demonstrated synergistic anti-proliferative efficacy in MDAMB231 and A375 cells involving apoptotic mode of cell death. The selective nature of the present combination module was supported by low off-target response in L132 non-cancerous lung cells. Moreover, the size of three-dimensional MDAMB231 spheroids was successfully reduced because of the combination therapy projecting its potential in eradicating tumor in vivo.
- 22 March 2019
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 5 (5) , 2222-2234
Combination Therapy with MAPK-Pathway-Specific Inhibitor and Folic-Acid-Receptor-Targeted Selenium Nanoparticles Induces Synergistic Antiproliferative Response in BRAF Mutant Cancer Cells
Combination chemotherapy, where drugs with non-overlapping mode of actions achieve better efficacy at lower doses with reduced dose-dependent side effects, holds promise for complete remission of tumor. Herein, we report a combination therapeutic module comprised of folic acid receptor (FAR)-targeted SeNPs (FA-SeNPs) and MAPK pathway inhibitor PD98059 (PD98). While aberrant signaling leading to uncontrolled proliferation in BRAF-mutation bearing cancer cells including MDAMB231 (breast cancer) and A375 (melanoma) cells was inhibited by PD98, high expression of FAR by these cells also led to selective internalization of FA-SeNPs. Consequently, the combination treatment of PD98 and FA-SeNPs demonstrated synergistic anti-proliferative efficacy in MDAMB231 and A375 cells involving apoptotic mode of cell death. The selective nature of the present combination module was supported by low off-target response in L132 non-cancerous lung cells. Moreover, the size of three-dimensional MDAMB231 spheroids was successfully reduced because of the combination therapy projecting its potential in eradicating tumor in vivo.